GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today outlined its 2025 strategic milestones ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

Welcome to the Confluent Q4 and fiscal year 2024 earnings conference call. I'm Shane Xie from investor relations, and I'm ...

Dr. Montgomery Rice will be formally recognized at the Atlanta Business Chronicle's second annual Health Care Champion Awards ceremony on March 20, 2025.

Advanced Therapeutics Pharmaceutical Outsourcing IndustryFuture Market Insights (FMI), a leading provider of industry analysis and market research, has unveiled its latest report highlighting the ...

Republished on January 22 with a new warning about the Generative AI tools now coming as standard from Google, Microsoft and others, and critical mitigation, as well as new security advice for those ...

which can be easily accommodated within a single AAV vector, while leaving ample room for additional ... systems at Mammoth and are excited to share the first demonstration of robust in vivo ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Jeff Vestal, principal customer enterprise architect at Elastic, joined DBTA's webinar, Beyond RAG basics: Strategies and best practices for implementing RAG, to explore best practices, patterns, and ...

Luxturna and other Spark pipeline candidates use an adeno-associated virus vector (AVV ... from this transaction to continue to develop our robust pipeline of investigational gene therapies ...